Tam FrySector leader
chair of the National Obesity Forum
Cited in UK press coverage of health & social care
1 citation
Across 1 topic, first on 27 Aug 2026.
Expertise
Cited on
What they’ve said
“Orforglipron [could prove] itself as the treatment of choice for the very obese diabetic. Its real bonus is in its straightforward use. When it is finally released, its availability must be more strictly controlled than semaglutide to avoid similar life-threatening usage.”
chair of the National Obesity Forum · Diabetes · 27 Aug 2026 · New GLP-1 pill helps patients lose up to 8% of body weight, trial shows ↗
Source references
- New GLP-1 pill helps patients lose up to 8% of body weight, trial showstheguardian.com · 27 Aug 2026
Chief executives, directors and spokespeople of trade bodies, representative associations and charities speaking for the sector. Citations are counted by an automated scan of UK press coverage and may be incomplete. Roles, biographies and contact details are researched and human-reviewed before they appear here; anything not yet reviewed is simply absent rather than shown unverified. See the methodology for how this page is built, or email contact@bridgeheadcommunications.com to correct anything on it.